Skytrofa is a long-acting form of somatropin. Somatropin is also called human growth hormone. Skytrofa is also considered a pegylated somatropin product. Pegylated means the medication is attached to ...

What Is Skytrofa, and Why Does It Matter? Skytrofa (lonapegsomatropin-tcgd) is a long-acting version of human growth hormone (hGH). It is already approved for children with growth hormone deficiency ...

Ascendis Pharma announced that the US Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11 ...

Lonapegsomatropin statistically significantly reduced trunk percent fat at week 38 compared with placebo (-1.7% vs 0.4%, respectively) in adult GHD patients. The Food and Drug Administration (FDA) has ...

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new ...

SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] SINGAPORE, May 29, 2025 /PRNewswire/ -- ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...